Understanding the placebo effect in clinical trials for postural tachycardia syndrome

Victor C. Nwazue, Amy Arnold, Vidya Raj, Bonnie K. Black, Italo Biaggioni, Sachin Y. Paranjape, Carlos Orozco, William D. Dupont, David Robertson, Satish R. Raj

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Summary: Postural tachycardia syndrome (POTS) is characterized by excessive increases in heart rate (HR) upon standing. Previous studies have shown that standing HR decreases over time in POTS patients given placebo. We hypothesized that this reduction is due to cardiovascular physiological alteration, as opposed to psychological benefit from perceived therapy. To prospectively test this hypothesis, we examined the effects of an open-label 'no treatment' intervention (NoRx) compared with a patient-blinded placebo on standing HR in POTS patients. Twenty-one POTS patients participated in a randomized cross-over trial with oral placebo versus NoRx administered at 0900 h. Seated blood pressure (BP) and HR were measured at baseline and every hour for 4 h. Similarly, BP and HR were measured while patients stood for 10 min at these time points. Standing HR decreased significantly over time with both NoRx (112 ± 13 and 103 ± 16 b.p.m. at baseline and 4 h, respectively) and placebo (112 ± 14 and 102 ± 16 b.p.m. at baseline and 4 h, respectively; Ptime < 0.001), but this effect was not different between interventions (Pdrug = 0.771). Postural tachycardia syndrome patients have exaggerated orthostatic tachycardia in the morning that decreases over time with either placebo or NoRx interventions, suggesting this phenomenon is due to cardiovascular physiological variation. These data highlight the need for a placebo arm in haemodynamic clinical trials in POTS and may have important implications for the diagnosis of these patients.

Original languageEnglish (US)
Pages (from-to)325-330
Number of pages6
JournalClinical and Experimental Pharmacology and Physiology
Volume41
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Postural Orthostatic Tachycardia Syndrome
Placebo Effect
Clinical Trials
Heart Rate
Placebos
Blood Pressure
Tachycardia
Cross-Over Studies
Hemodynamics
Psychology

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Nwazue, Victor C. ; Arnold, Amy ; Raj, Vidya ; Black, Bonnie K. ; Biaggioni, Italo ; Paranjape, Sachin Y. ; Orozco, Carlos ; Dupont, William D. ; Robertson, David ; Raj, Satish R. / Understanding the placebo effect in clinical trials for postural tachycardia syndrome. In: Clinical and Experimental Pharmacology and Physiology. 2014 ; Vol. 41, No. 5. pp. 325-330.
@article{2eb9072990e24129b9c558979a55d03b,
title = "Understanding the placebo effect in clinical trials for postural tachycardia syndrome",
abstract = "Summary: Postural tachycardia syndrome (POTS) is characterized by excessive increases in heart rate (HR) upon standing. Previous studies have shown that standing HR decreases over time in POTS patients given placebo. We hypothesized that this reduction is due to cardiovascular physiological alteration, as opposed to psychological benefit from perceived therapy. To prospectively test this hypothesis, we examined the effects of an open-label 'no treatment' intervention (NoRx) compared with a patient-blinded placebo on standing HR in POTS patients. Twenty-one POTS patients participated in a randomized cross-over trial with oral placebo versus NoRx administered at 0900 h. Seated blood pressure (BP) and HR were measured at baseline and every hour for 4 h. Similarly, BP and HR were measured while patients stood for 10 min at these time points. Standing HR decreased significantly over time with both NoRx (112 ± 13 and 103 ± 16 b.p.m. at baseline and 4 h, respectively) and placebo (112 ± 14 and 102 ± 16 b.p.m. at baseline and 4 h, respectively; Ptime < 0.001), but this effect was not different between interventions (Pdrug = 0.771). Postural tachycardia syndrome patients have exaggerated orthostatic tachycardia in the morning that decreases over time with either placebo or NoRx interventions, suggesting this phenomenon is due to cardiovascular physiological variation. These data highlight the need for a placebo arm in haemodynamic clinical trials in POTS and may have important implications for the diagnosis of these patients.",
author = "Nwazue, {Victor C.} and Amy Arnold and Vidya Raj and Black, {Bonnie K.} and Italo Biaggioni and Paranjape, {Sachin Y.} and Carlos Orozco and Dupont, {William D.} and David Robertson and Raj, {Satish R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/1440-1681.12221",
language = "English (US)",
volume = "41",
pages = "325--330",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "5",

}

Nwazue, VC, Arnold, A, Raj, V, Black, BK, Biaggioni, I, Paranjape, SY, Orozco, C, Dupont, WD, Robertson, D & Raj, SR 2014, 'Understanding the placebo effect in clinical trials for postural tachycardia syndrome', Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 5, pp. 325-330. https://doi.org/10.1111/1440-1681.12221

Understanding the placebo effect in clinical trials for postural tachycardia syndrome. / Nwazue, Victor C.; Arnold, Amy; Raj, Vidya; Black, Bonnie K.; Biaggioni, Italo; Paranjape, Sachin Y.; Orozco, Carlos; Dupont, William D.; Robertson, David; Raj, Satish R.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 41, No. 5, 01.01.2014, p. 325-330.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Understanding the placebo effect in clinical trials for postural tachycardia syndrome

AU - Nwazue, Victor C.

AU - Arnold, Amy

AU - Raj, Vidya

AU - Black, Bonnie K.

AU - Biaggioni, Italo

AU - Paranjape, Sachin Y.

AU - Orozco, Carlos

AU - Dupont, William D.

AU - Robertson, David

AU - Raj, Satish R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Summary: Postural tachycardia syndrome (POTS) is characterized by excessive increases in heart rate (HR) upon standing. Previous studies have shown that standing HR decreases over time in POTS patients given placebo. We hypothesized that this reduction is due to cardiovascular physiological alteration, as opposed to psychological benefit from perceived therapy. To prospectively test this hypothesis, we examined the effects of an open-label 'no treatment' intervention (NoRx) compared with a patient-blinded placebo on standing HR in POTS patients. Twenty-one POTS patients participated in a randomized cross-over trial with oral placebo versus NoRx administered at 0900 h. Seated blood pressure (BP) and HR were measured at baseline and every hour for 4 h. Similarly, BP and HR were measured while patients stood for 10 min at these time points. Standing HR decreased significantly over time with both NoRx (112 ± 13 and 103 ± 16 b.p.m. at baseline and 4 h, respectively) and placebo (112 ± 14 and 102 ± 16 b.p.m. at baseline and 4 h, respectively; Ptime < 0.001), but this effect was not different between interventions (Pdrug = 0.771). Postural tachycardia syndrome patients have exaggerated orthostatic tachycardia in the morning that decreases over time with either placebo or NoRx interventions, suggesting this phenomenon is due to cardiovascular physiological variation. These data highlight the need for a placebo arm in haemodynamic clinical trials in POTS and may have important implications for the diagnosis of these patients.

AB - Summary: Postural tachycardia syndrome (POTS) is characterized by excessive increases in heart rate (HR) upon standing. Previous studies have shown that standing HR decreases over time in POTS patients given placebo. We hypothesized that this reduction is due to cardiovascular physiological alteration, as opposed to psychological benefit from perceived therapy. To prospectively test this hypothesis, we examined the effects of an open-label 'no treatment' intervention (NoRx) compared with a patient-blinded placebo on standing HR in POTS patients. Twenty-one POTS patients participated in a randomized cross-over trial with oral placebo versus NoRx administered at 0900 h. Seated blood pressure (BP) and HR were measured at baseline and every hour for 4 h. Similarly, BP and HR were measured while patients stood for 10 min at these time points. Standing HR decreased significantly over time with both NoRx (112 ± 13 and 103 ± 16 b.p.m. at baseline and 4 h, respectively) and placebo (112 ± 14 and 102 ± 16 b.p.m. at baseline and 4 h, respectively; Ptime < 0.001), but this effect was not different between interventions (Pdrug = 0.771). Postural tachycardia syndrome patients have exaggerated orthostatic tachycardia in the morning that decreases over time with either placebo or NoRx interventions, suggesting this phenomenon is due to cardiovascular physiological variation. These data highlight the need for a placebo arm in haemodynamic clinical trials in POTS and may have important implications for the diagnosis of these patients.

UR - http://www.scopus.com/inward/record.url?scp=84899114899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899114899&partnerID=8YFLogxK

U2 - 10.1111/1440-1681.12221

DO - 10.1111/1440-1681.12221

M3 - Article

C2 - 24606242

AN - SCOPUS:84899114899

VL - 41

SP - 325

EP - 330

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 5

ER -